Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01195363 · ClinicalTrials.gov registry record · Phase 4

Quetiapine Sr as Adjunctive Treatment In Mixed States of Bipolar Disorder

A Phase 4 study, sponsored by The University of Texas Health Science Center at San Antonio.

Completed
Registry status
Phase 4
Development phase
28
Enrollment target

NCT01195363: Completed Phase 4 study, sponsored by The University of Texas Health Science Center at San Antonio.

NCT01195363 is a Phase 4 study that has completed, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 28 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01195363, a Phase 4 study, has completed, sponsored by The University of Texas Health Science Center at San Antonio.

COMPLETED
Registry status
Phase 4
Development phase
28 participants
Enrollment target

Study Summary

To assess the acute and long-term bimodal efficacy of QTP, as an adjunct to ongoing treatment with lithium (Li) or divalproex (DIV) or lamotrigine (LAM) or any combination of the three thereof, in a group of patients with an index episode of a mixed state in BD.

Primary Outcome

The primary outcome measure was assessed by 50% reduction in: 1. depression scores on the Montgomery Asberg Depression Rating Scale (MADRS), which ranges from 0 indicating no symptoms to 60 indicating most symptoms 2. mania scores on the Young Mania Rating Scale (YMRS), which ranges from 0 indicating no symptoms to 60 indicating most symptoms.

Interventions

  • DRUG quetiapine SR
  • DRUG quetiapine sr placebo

Trial Details

FieldValue
Enrollment Target 28 participants
Start Date 2007-04
Est. Completion 2011-06
Phase Phase 4

What the finished NCT01195363 record still lists

NCT01195363 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower).

The record links to 0 conditions, and to 2 interventions - of which quetiapine SR is the first listed.

NCT01195363 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01195363 about?

NCT01195363 is a clinical study titled "Quetiapine Sr as Adjunctive Treatment In Mixed States of Bipolar Disorder". To assess the acute and long-term bimodal efficacy of QTP, as an adjunct to ongoing treatment with lithium (Li) or divalproex (DIV) or lamotrigine (LAM) or any combination of the three thereof, in a group of patients with an index episode of a mixed state in BD.

What is the current status of trial NCT01195363?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 28 participants. The study started on 2007-04. Estimated completion is 2011-06.

What interventions are being tested in trial NCT01195363?

The interventions under investigation include: quetiapine SR (DRUG), quetiapine sr placebo (DRUG).

Who is sponsoring clinical trial NCT01195363?

This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01195363's enrollment target sits among peer trials

28 1635th of 2000 higher than 350 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03471117 · 28 participants · Phase 4

    Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients

  • NCT03523975 · 28 participants · Phase 1

    Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma

  • NCT03608631 · 28 participants · Phase 1

    iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation

  • NCT03810651 · 28 participants · Early Phase 1

    Pencil Beam Scanning in Patients With Renal Tumors

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01195363, the US trial registry maintained by the National Library of Medicine. NCT01195363 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.